Psychomotor slowing, negative symptoms and dopamine receptor availability - An IBZM SPECT study in neuroleptic-treated and drug-free schizophrenic patients

Schizophrenia Research

Volumn 31, Issue 1, 1998, Pages 19-26

  Heinz, Andreas ^a,b   Knable, Michael B ^a   Coppola, Richard ^a   Gorey, Julia G ^a   Jones, Douglas W ^a   Lee, Kan Sam ^a   Weinberger, Daniel R ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^b RUHR UNIVERSITY BOCHUM   (Germany)

Author keywords

I 123 IBZM SPECT; Negative symptoms; Psychomotor slowing; Schizophrenia

Indexed keywords

DOPAMINE 2 RECEPTOR; DOPAMINE 3 RECEPTOR; N [(1 ETHYL 2 PYRROLIDINYL)METHYL] 3 IODO 6 METHOXYSALICYLAMIDE;

ADULT; ANHEDONIA; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CORPUS STRIATUM; DOPAMINERGIC SYSTEM; HUMAN; ISOTOPE LABELING; PRIORITY JOURNAL; PSYCHOMOTOR ACTIVITY; RECEPTOR DENSITY; SCHIZOPHRENIA; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

ACUTE DISEASE; ADULT; ANTIPSYCHOTIC AGENTS; BENZAMIDES; BRAIN; DOPAMINE ANTAGONISTS; HALOPERIDOL; HUMANS; MIDDLE AGED; PSYCHOMOTOR DISORDERS; PYRROLIDINES; REACTION TIME; RECEPTORS, DOPAMINE; RISPERIDONE; SCHIZOPHRENIA; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 0032482111     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0920-9964(98)00003-6     Document Type: Article

References (31)

1. American Psychiatric Association, 1994. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. American Psychiatric Association Press, Washington, DC.
2. Andreasen, N.C., 1982. Negative symptoms in schizophrenia. Arch. Gen. Psychiatry 39, 784-788.
3. Andreasen, N.C., 1984. Scale for the Assessment of Negative Symptoms. University of Iowa, Iowa City.
4. Bigelow, L.B., Berthot, B.D., 1989. The psychiatric symptom assessment scale. Psychopharmacol. Bull. 25, 168-179.
5. Brodie, M.S., Bunney, E.B., 1996. Serotonin potentiates dopamine inhibition of ventral tegmental area neurons in vitro. J. Neurophysiol. 76, 2077-2082.
6. Chatterjee, A., Chakos, M., Koreen, A., Geisler, S., Sheitman, B., Woerner, M., Kane, J.M., Alvir, J., Lieberman, J.A., 1995. Prevalence and clinical correlates of extrapyramidal signs and spontaneous dyskinesia in never-medicated schizophrenic patients. Am. J. Psychiatry 152, 1724-1729.
7. Classen, W., Laux, G., 1989. Comparison of sensorimotor and cognitive performance of acute schizophrenic inpatients treated with remoxipride or haloperidol. Neuropsychobiology 21, 131-140.
8. Classen, W., Laux, G., 1991. Psychometrische Untersuchungen von Leistungsdefiziten bei akut schizophren erkrankten Patienten unter besonderer Berücksichtigung des Geschlechts. Schweiz. Archiv. Neurol. Psychiatr. 142, 31-40.
9. Fishman, J., Schwartz, F., Bertuch, E., Lesser, B., Reseigno, D., Viegener, B., 1991. Laterality in schizophrenia. A reaction time study. Eur. Arch. Psychiatry Clin. Neurosci. 241, 126-130.
10. Guy, W., Ban, T.A., 1982. The AMDP-System. Manual for the Assessment and Documentation of Psychopathology. Springer Verlag, Berlin.
11. Heinz, A., Schmidt, L.G., Reischies, F., 1994. Anhedonia in schizophrenic, depressed, or alcohol-dependent patients neurobiological correlates. Pharmacopsychiatry 27 (Suppl.), 7-10.
12. 2 receptor imaging and neuroleptic drug response. J. Clin. Psychiatry 57 (suppl. 11), 84-88.
13. Helmchen, H., Hippius, H., 1967. Depressive Syndrome im Verlauf neuroleptischer Therapie. Nervenarzt 38, 455-468.
14. 2 antagonistic properties. J. Pharmacol. Exp. Ther. 244, 685-693.
15. Jordan, N., Sagar, H.J., Cooper, J.A., 1992. Cognitive components of reaction time in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 55, 658-664.
16. Knable, M.B., Jones, D.W., Coppola, R., Hyde, T.M., Lee, K.S., Gorey, J., Weinberger, D.R., 1995. Lateralized differences in iodine-123-IBZM uptake in the basal ganglia in asymmetric Parkinson's disease. J. Nucl. Med. 36, 1216-1225.
17. Knable, M.B., Egan, M.F., Heinz, A., Gorcy, J., Lee, K.S., Coppola, R., Weinberger, D.R., 1997a. Altered dopaminergic function and negative symptoms in drug-free patients with schizophrenia. Br. J. Psychiatry 171, 574-577.
18. 2 receptor occupancy levels. Psychiatry Res. Neuroimaging 75, 91-101.
19. 2 receptor imaging agent. J. Radiopharmacol. Lab. Comp. 27, 691-700.
20. Kung, H.F., Alavi, A., Chang, W., Kung, M.P., Keyes, J.W., Velchik, M.G., Billings, J., Pan, S., Noto, R., Rausch, A., Reilley, J., 1990. In vivo SPECT imaging of CNS D-2 dopamine receptors: initial studies with iodine-123-IBZM in humans. J. Nucl. Med. 31, 573-579.
21. 2 receptors in healthy subjects. J. Nucl. Med. 35, 743-754.
22. Oldfield, R.C., 1979. The assessment and analysis of handedness: the Edinburgh Inventory. Neuropsychology 9, 97-113.
23. Robinson, T.E., Berridge, K.C., 1993. The neural basis of drug craving: an incentive-sensitization theory of addiction. Brain Res. Rev. 18, 247-291.
24. Schwartz, F., Munich, R.L., Carr, A., Bartuch, E., Lesser, B., Rescigno, D., Viegener, B., 1991. Negative symptoms and reaction time in schizophrenia. J. Psychiatr. Res. 25, 131-140.
25. 2 dopamine receptor occupancy: a crossover comparison of risperidone with clozapine therapy in schizophrenic patients. Arch Gen Psychiatry 54, 972
26. van Woert, M.H., 1983. Neuroleptics in neurological disorder. In: Coyle, J.T., Enna, S.J. (Eds.), Neuroleptics: Neurochemical, Behavioral, and Clinical Perspectives. Raven Press, New York, pp. 65-74.
27. Walker, E., Green, M., 1982. Motor proficiency and attentional-task performance by psychotic patients. J. Abnorm. Psychol. 91, 261-268.
28. Weinberger, D.R., 1987. Implications of normal brain development for the pathogenesis of schizophrenia. Arch. Gen. Psychiatry 44, 660-669.
29. Wise, R.A., 1988. The neurobiology of craving: implications for the understanding of addiction. J. Abnorm. Psychol. 97, 118-132.
30. 2 receptor binding explains phenotypic variation in monozygotic twins. Science 273, 1225-1226.
31. Wyatt, R.J., 1993. Practical psychiatric practice: clinical interview forms, rating scales and patient handouts. American Psychiatric Association Press, Washington, DC.